Valneva shares down 8.5% over five sessions ahead of its November 24 results
The Lyon-based vaccine maker is trading lower at midday, in a Paris session strongly tilted to the downside. The stock sits in the lower part of its index and remains well below its medium- and long-term reference levels, a few days before its next results.
A decline that extends the slide below the three moving averages
Valneva shares fall 2% to €2.40, while the SBF 120 loses 1.2% and the CAC 40 drops 1.15%. This decline wipes out the previous day's rebound and brings the weekly decline to 8.8%, after a quarter at -17.2%.
The stock is now below its MA20 at €2.52 (a gap of -4.7%), below its MA50 at €2.59 and below its MA200 at €2.81, which shows how far the price has moved away from its longer-term references.
Valneva ranks at the bottom of the index, far behind Sanofi, which rises 1.7% in the same session. The support at €2.33 is less than 3% below the current price, and the RSI at 41 remains in neutral territory.
Nine-month results expected on November 24
The company will publish its results for the first nine months on November 24. In its first-half 2026 results, published on August 13, it confirmed its outlook for the year despite the persistent impact of the geopolitical context on travel.
Among the risks cited on that occasion was the dependence on deliveries of IXIARO to the U.S. Department of Defense, whose timing remains uncertain.
Valneva had also mentioned regulatory decisions expected within the following twelve months on its Lyme disease vaccine candidate. The stock, listed in Paris and traded as ADS on the Nasdaq, is now looking ahead to this publication, with its support at €2.33 as the nearest level.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
EBITDA margin: -60,4 %
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.